TELA Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 at 04:07 pm EST
Share
TELA Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 11.16 million compared to USD 7.65 million a year ago. Net loss was USD 10.71 million compared to USD 8.27 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.57 a year ago.
For the nine months, sales was USD 29.8 million compared to USD 21.09 million a year ago. Net loss was USD 34.32 million compared to USD 24.66 million a year ago. Basic loss per share from continuing operations was USD 2.24 compared to USD 1.71 a year ago.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.